Literature DB >> 9617922

Cellular and subcellular sites for noradrenergic action in the monkey dorsolateral prefrontal cortex as revealed by the immunocytochemical localization of noradrenergic receptors and axons.

C Aoki1, C Venkatesan, C G Go, R Forman, H Kurose.   

Abstract

A series of electron microscopic immunocytochemical studies was performed to analyze subcellular sites for noradrenergic modulation in monkey prefrontal cortex. One out of 12 noradrenergic varicosities, identified by dopamine beta-hydroxylase immunocytochemistry within single ultrathin sections, forms morphologically identifiable junctions with small dendrites and spines. Accordingly, alpha2-adrenergic receptors, almost all of which are of the A-subtype, that occur in spines are localized discretely over postsynaptic membranes. alpha2-Adrenergic receptors are also found at sites along axons, dendritic shafts and astrocytic processes lacking morphologically identifiable synaptic junctions, suggesting that these receptors are activated by volume transmission. In particular, axonal alpha2-adrenergic receptors occur mostly at pre-terminal regions, suggesting that axo-axonic interactions may mediate reduction of neurotransmitter release at sites other than axo-spinous junctions by closing voltage-dependent calcium channels. These results indicate that noradrenergic modulation of prefrontal cortex involves synaptic interactions at spines of pyramidal neurons and nonsynaptic volume transmission to glia, dendritic shafts and axons.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9617922     DOI: 10.1093/cercor/8.3.269

Source DB:  PubMed          Journal:  Cereb Cortex        ISSN: 1047-3211            Impact factor:   5.357


  49 in total

Review 1.  Use of electron microscopy in the detection of adrenergic receptors.

Authors:  C Aoki; S Rodrigues; H Kurose
Journal:  Methods Mol Biol       Date:  2000

Review 2.  The use of α-2A adrenergic agonists for the treatment of attention-deficit/hyperactivity disorder.

Authors:  Amy F T Arnsten
Journal:  Expert Rev Neurother       Date:  2010-10       Impact factor: 4.618

3.  Neuron specific alpha-adrenergic receptor expression in human cerebellum: implications for emerging cerebellar roles in neurologic disease.

Authors:  U B Schambra; G B Mackensen; M Stafford-Smith; D E Haines; D A Schwinn
Journal:  Neuroscience       Date:  2005       Impact factor: 3.590

4.  α₂- and β-adrenoceptors involvement in nortriptyline modulation of auditory sustained attention and impulsivity.

Authors:  Swagata Roychowdhury; Zulma Peña-Contreras; Jason Tam; Amulya Yadlapalli; Lu Dinh; Justin Andrew Nichols; Debarshi Basu; Marco Atzori
Journal:  Psychopharmacology (Berl)       Date:  2012-01-21       Impact factor: 4.530

Review 5.  Adrenergic pharmacology and cognition: focus on the prefrontal cortex.

Authors:  Brian P Ramos; Amy F T Arnsten
Journal:  Pharmacol Ther       Date:  2006-12-28       Impact factor: 12.310

6.  alpha2-Noradrenergic receptors activation enhances excitability and synaptic integration in rat prefrontal cortex pyramidal neurons via inhibition of HCN currents.

Authors:  David B Carr; Glenn D Andrews; William B Glen; A Lavin
Journal:  J Physiol       Date:  2007-08-16       Impact factor: 5.182

7.  Locus coeruleus alpha-adrenergic-mediated activation of cortical astrocytes in vivo.

Authors:  Lane K Bekar; Wei He; Maiken Nedergaard
Journal:  Cereb Cortex       Date:  2008-03-27       Impact factor: 5.357

Review 8.  Non-synaptic receptors and transporters involved in brain functions and targets of drug treatment.

Authors:  E S Vizi; A Fekete; R Karoly; A Mike
Journal:  Br J Pharmacol       Date:  2010-02-05       Impact factor: 8.739

Review 9.  HCN Channel Targets for Novel Antidepressant Treatment.

Authors:  Stacy M Ku; Ming-Hu Han
Journal:  Neurotherapeutics       Date:  2017-07       Impact factor: 7.620

10.  Adrenergic and noradrenergic innervation of the midbrain ventral tegmental area and retrorubral field: prominent inputs from medullary homeostatic centers.

Authors:  Carlos A Mejías-Aponte; Candice Drouin; Gary Aston-Jones
Journal:  J Neurosci       Date:  2009-03-18       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.